Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

STRO

Sutro Biopharma (STRO)

Sutro Biopharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:STRO
DateTimeSourceHeadlineSymbolCompany
01/07/20253:05PMGlobeNewswire Inc.Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference NASDAQ:STROSutro Biopharma Inc
01/07/20258:00AMGlobeNewswire Inc.Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scaleNASDAQ:STROSutro Biopharma Inc
12/10/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
12/10/20247:00AMGlobeNewswire Inc.Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian CancerNASDAQ:STROSutro Biopharma Inc
12/03/20243:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
11/14/20246:54PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
11/13/20243:34PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
11/13/20243:30PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
11/13/20243:30PMGlobeNewswire Inc.Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:STROSutro Biopharma Inc
11/12/20248:34AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STROSutro Biopharma Inc
11/04/20243:05PMGlobeNewswire Inc.Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC ConferenceNASDAQ:STROSutro Biopharma Inc
11/01/20247:00AMGlobeNewswire Inc.Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AMLNASDAQ:STROSutro Biopharma Inc
10/10/20243:05PMGlobeNewswire Inc.Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research ForumNASDAQ:STROSutro Biopharma Inc
09/20/20243:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
09/20/20243:01PMGlobeNewswire Inc.Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:STROSutro Biopharma Inc
09/14/20242:00AMGlobeNewswire Inc.Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024NASDAQ:STROSutro Biopharma Inc
09/11/20247:00AMGlobeNewswire Inc.Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024NASDAQ:STROSutro Biopharma Inc
08/22/20247:00AMGlobeNewswire Inc.Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung CancerNASDAQ:STROSutro Biopharma Inc
08/13/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STROSutro Biopharma Inc
08/13/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
08/13/20243:30PMGlobeNewswire Inc.Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated MilestonesNASDAQ:STROSutro Biopharma Inc
08/13/20243:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
08/12/20243:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
08/12/20243:38PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
08/12/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
07/10/20243:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/10/20243:10PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
07/09/20247:00AMGlobeNewswire Inc.Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development OfficerNASDAQ:STROSutro Biopharma Inc
06/10/20243:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STROSutro Biopharma Inc
06/10/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:STROSutro Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:STRO